Avaliação Preliminar da Fampridina na Esclerose Múltipla: Para Além da Velocidade da Marcha

Abstract

Introduction : The purpose of this study is to assess the impact of fampridine on walking, balance and perception of walking capacity in multiple sclerosis patients. Material and Methods : Prospective, open-label, non-controlled and non-randomized study on multiple sclerosis patients with an Expanded Disability Status scale (EDSS) between 4 and 7, treated with fampridine. For the evaluation of the impact of fampridine were used: Multiple Sclerosis Walking scale 12 (MSWS-12), Timed 25-Foot Walk (T25FW), Timed Up and Go (TUG) and Berg scale. The results were statistically analysed with statistical significance set to p < 0.05. Results : A total of 15 patients (88.24%) were considered responders. The improvement in balance, gait velocity and perception on walking capacity were statistically significant with mean value of 19.08% (± 31.11) on T25FW (p = 0.022), 19.20% (± 26.13) on BBS (p = 0.012), 35.97% (± 34.93) on TUG (p = 0.022) and 12.99% (± 12.90) on MSWS-12 (p = 0.016). This study showed a strong and statistically significant correlation between TUG and T25FW (r = 0.668, p = 0.017). Conclusion : The preliminary results show fampridine potential for gait, balance improving and improvement on perception of walking capacity. Further research is needed to identify and characterize predictors of responsiveness and evaluate other potential functional outcomes.